ERBB2 and breast carcinoma: Breast cancer resistance to chemotherapy, including tyrosine kinase inhibitors, is associated with the constant activation of the phosphatidylinositol pathway, which may cause increased expression of epidermal growth factor receptors (HER2 and HER3).